NICE guidance on vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma

Lancet Oncol. 2013 Jan;14(1):20-1. doi: 10.1016/s1470-2045(12)70565-x.
No abstract available

Publication types

  • News

MeSH terms

  • Humans
  • Indoles / administration & dosage*
  • Melanoma* / drug therapy
  • Melanoma* / genetics
  • Melanoma* / pathology
  • Mutation
  • Neoplasm Metastasis / drug therapy*
  • Neoplasm Recurrence, Local / drug therapy*
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors
  • Proto-Oncogene Proteins B-raf / genetics
  • Sulfonamides / administration & dosage*
  • Vemurafenib

Substances

  • Indoles
  • Sulfonamides
  • Vemurafenib
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf